Direct-acting antiviral (DAA) therapy, recently approved for patients with decompensated cirrhosis (DC) secondary to hepatitis C virus (HCV), is associated with improved hepatic function. We analyzed trends in liver transplant (LT) waitlisting (WL) to explore potential impact of effective medical therapy on WL registration. This is a cohort study using the Scientific Registry of Transplant Recipients database from 2003 to 2015. A total of 47,591 adults wait-listed for LT from HCV, hepatitis B virus (HBV), and nonalcoholic steatohepatitis (NASH) were identified. LT indication was defined as DC if the Model for End-Stage Liver Disease (MELD) at WL was 15 or hepatocellular carcinoma (HCC). Era of listing was divided into interferon (IFN; 2003, protease inhibitor (PI; 2011 , and direct-acting antiviral (DAA;. Annual standardized incidence rates of WL were analyzed using Poisson regression. Adjusted incidences of LT WL for DC in HCV patients decreased by 5% in the PI era (P 5 0.004) and 32% in the DAA era (P < 0.001) compared to the IFN era. Listing for DC in HBV also decreased in the PI (-17%; P 5 0.002) and DAA eras (-24%; P < 0.001). Conversely, WL for DC in NASH increased by 41% in the PI era (P < 0.001) and 81% in the DAA era (P < 0.001). WL for HCC in both the HCV and NASH populations increased in both the PI and DAA eras (P < 0.001 for all) whereas HCC WL in HBV remained stable (P > 0.05 for all). Conclusion: The rate of LT WL for HCV complicated by DC has decreased by over 30% in the era of DAA therapy. Further reductions in WL are anticipated with increased testing, linkage to care, and access to DAA therapy. (HEPATOLOGY 2017;65:804-812).
L iver transplantation (LT) is a well-established therapy for patients with cirrhosis who have developed hepatic decompensation and small hepatocellular carcinoma (HCC). Viral hepatitis (VH) has long been the most common indication for LT in the United States and Canada, with over 30% of all LT wait-listed candidates having chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. (1) It has been estimated that the complications of decompensated cirrhosis (DC) and HCC from HCV infection will continue to rise into the next decade, resulting in increased utilization of health care resources, including LT, for these populations. (2, 3) It has been shown that effective antiviral therapy (AVT) resulting in either chronic viral suppression for those Abbreviations: ASIR, age-standardized incidence rate; AVT, antiviral therapy; BMI, body mass index; DAAs, direct-acting antivirals; DC, decompensated cirrhosis; FDA, U.S. Food and Drug Administration; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; IFN, interferon; IQR, interquartile ratio; IRR, incidence rate ratio; LT, liver transplant; MELD, Model for End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; OPTN, Organ Procurement and Transplantation Network; PI, protease inhibitor; SRTR, Scientific Registry of Transplant Recipients; SVR, sustained virologic response; VH, viral hepatitis; WL, wait-listing.
with HBV, or "cure" with a sustained virological response (SVR) in those with HCV, results in decreased rates of HCC, DC, and LT, as well as a decrease in overall mortality. (4, 5) Our previous work spanning the years of 1994-2006 has shown that LT for DC and acute hepatic failure in patients with HBV were significantly lower from 2003 to 2006 compared to 1994-1997 in the United States. (6) Although the observation was ecological without a direct demonstration of cause-effect relationship, the trend was attributed to the availability of U.S. Food and Drug Administration (FDA)-approved effective oral AVT for HBV with an improved resistance profile, starting in 2002.
The availability of effective, well-tolerated AVTs in the United States has evolved differently for HBV as compared to HCV (Supporting Fig. S1 ), with an almost 15-year difference in access to all-oral treatment regimens for the two viruses. Potent and safe chronic AVTs for patients with HBV, including those with cirrhosis, have been FDA approved and available for more than a decade. (8) In contrast, safe and highly effective direct-acting antivirals (DAAs) for HCV have only been available in the United States since 2014. (9) DAA therapy for HCV is curative and of a finite duration as opposed to chronic suppressive therapy in the majority of HBV cases. Current DAA combination therapy can achieve SVR in the majority of patients with HCV cirrhosis, both compensated and decompensated, and among those with DC and SVR, improvements in the Model for End-Stage Liver Disease (MELD) and Child-Turcotte-Pugh scores in months of completing treatment. (10) (11) (12) (13) Furthermore, achievement of SVR in patients with cirrhosis has been associated with significant reductions in liver-related complications, such as decompensation and HCC. (4) It is estimated that over 100 million people in the United States have nonalcoholic fatty liver disease, and of those, 15-20 million will have nonalcoholic steatohepatitis (NASH). (14) NASH is a recognized cause of cirrhosis and HCC, and recent studies have shown that the rates of listing and receipt of LT for this indication have increased over the last decade. (5, 16) In contrast to VH, there are currently no FDA-approved therapies to decrease the risk of progression to DC or HCC or to reverse NASH-related liver fibrosis.
Given that wait-listing (WL) for LT is a reflection of the changing epidemiology of the underlying population with cirrhosis in the United States, the aims of this study were to evaluate the secular trends in LT WL registration for HCV, HBV, and NASH based on the indication for LT (DC or HCC) to estimate how the availability of effective treatments influences LT listing rates.
Patients and Methods

PATIENTS AND DATA ELEMENTS
This is a population-based cohort study of patients listed for LT from all 127 centers across the United States. This study used data from the Scientific Registry of Transplant Recipients (SRTR). The SRTR data system includes data on all donors, WL candidates, and transplant recipients in the United States, submitted by the members of the Organ Procurement and Transplantation Network (OPTN). The Health Resources and Services Administration, U.S. Department of Health and Human Services, provides oversight to the activities of the OPTN and SRTR contractors. (17) Focusing on a post-MELD time period (January 1, 2003-December 31, 2015), we identified all adult (18 years of age) WL registrants with an etiology of liver disease (based on primary or secondary SRTR diagnostic codes or manually entered text) of HBV, HCV, or NASH. Patients with a dual diagnosis of HCV and any other cause (i.e., alcohol) were classified as HCV. Following the previous convention, patients listed with a diagnosis of cryptogenic cirrhosis with a body
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From themass index (BMI) >30 were classified as NASH. (15, 16) Patients were excluded if they lacked a unique identifier, were listed for indications other than that in the inclusion criteria, listed as status 1, or had received a previous LT. Those who had previous transplantation of other organs were included (0.7% of cohort).
Patients were classified as being WL for indication of DC if their MELD at LT listing was 15 to capture those with uniform indications for LT for decompensated liver disease. Though we recognize that patients with a MELD <15 with complications of refractory ascites, hepatic hydrothorax, severe hepatic encephalopathy, or hepatopulmonary syndrome would be excluded, the SRTR data do not allow us to reliably capture this information. Patients were classified as being WL for the indication of HCC if it was identified as the listing indication (based on SRTR codes or manually entered text) and/or they received an HCC MELD exception within the first 180 days of transplant WL. If patients were listed with both HCC and a MELD score 15, they were classified as being listed with HCC. We divided the study period into three eras to reflect differences in availability of specific AVTs for HCV. Era 1-"interferon era (IFN)"-was from 2003 to 2010; era 2-"protease inhibitor (PI) era"-was from 2011 to 2013; and era 3-"DAA era"-was from 2014 to 2015.
Demographic and clinical data were obtained from the SRTR at the time of listing for LT. The proportion of patients with LT WL death or dropout was determined using SRTR codes. 
STATISTICAL ANALYSES
Demographics of the cohort are expressed as medians or percentages and compared using the Kruskall-Wallis or chi-squared tests, respectively. To test for secular trends over time in median age, MELD score, and proportion of patients with death/dropout or recovery on the WL, the nonparametric test for trend was used. (18) To calculate the age-standardized incidence rates (ASIRs) for LT WL, the number of patients listed annually by sex were tabulated into age categories using the entire annual U.S. population estimates as the denominator (http://www.census.gov/cps) and standardized to the 2000 U.S. population (http:// seer.cancer.gov/popdata/index/htm) using the direct method. Differences between the annual rates of transplant WL by indication were compared by calculating incidence rate ratios (IRRs) using zero-weighted Poisson regression adjusting for age and sex after confirming that this method was preferred over standard Poisson regression using the Vuong test. (19) All analyses were performed using STATA software (StataCorp 2011; Stata Statistical Software: Release 12; StataCorp LP, College Station, TX).
Results
BASELINE DEMOGRAPHICS OF THE COHORT
A total of 47,591 WL registrants met inclusion and exclusion criteria for the study (Fig. 1) . Median age of the cohort was 56 years (interquartile ratio [IQR], 51-61), 71% were male, and most patients were of Caucasian, non-Hispanic race/ethnicity ( Table 1) . The majority of patients were listed for DC (61%), with 39% being listed for HCC. Those with HCV and HBV had a higher proportion of individuals listed for HCC compared to those with NASH. Patients with NASH were older, more likely to have underlying diabetes, and a higher median BMI and biochemical MELD score at LT WL. Those with HBV were more likely to be of Asian race compared to those with HCV or NASH.
SECULAR TRENDS IN WL FOR LT BASED ON INDICATION AND ETIOLOGY OF DISEASE
The ASIR of LT WL by listing indication (overall, DC, and HCC) and the etiology of liver disease based on the total U.S. population are listed in Supporting  Table S1 and displayed in Fig. 2 . Secular trends in WL over the study period based on the underlying etiology of disease are shown in Fig. 3 . The ASIR rate for overall LT WL, over the 10-year study period, increased in those with HCV and NASH whereas it decreased in those with HBV. For the indication of DC, the ASIR decreased in those with HCV in and HBV in both the PI and DAA eras, but increased over 3-fold in those with NASH. If we consider these rates in the context of individual patient numbers, it suggests that there were almost 700 fewer HCV patients in the U.S. WL for DC in 2015 compared to 2003. Of importance, in 2015, the ASIR of LT WL for DC for NASH was similar to that for HCV (2.80 per 100,000 vs. 2.73 per 100,000, respectively). WL for the indication of HCC increased 2-fold for HCV and over 10-fold in the NASH population whereas it remained stable in those with HBV. Table 2 describes IRRs for the three eras for the different indication and etiology of underlying liver disease. For the HCV population, the overall rate of LT WL increased by 24% in the PI era, but decreased by 8% during the DAA era when compared to the IFN era. When focusing on WL for DC, the rate decreased by 5% during the PI era and 32% since FDA approval for DAA therapy when compared to 2003-2010. In contrast, listing for HCC in the HCV population increased by 62% in the PI era and 34% in the DAA era. In those with HBV, listing for DC decreased from both 2011-2013 and 2014-2015 whereas listing for HCC remained constant. For the NASH population, rates of LT WL increased overall and for both DC and HCC in both eras.
SECULAR TRENDS IN AGE AT WL, MELD SCORE, AND DROPOUT FROM THE WL AMONG PATIENTS LISTED WITH END-STAGE LIVER DISEASE
Other factors that could explain the secular trends in LT WL for DC were explored. First, to determine whether the observed trends were secondary to the aging population and, specifically, the "baby boomer" population of individuals with HCV, we calculated the median age at LT WL (Table 3) . Overall, median age at the time of WL increased significantly over the study period for all groups (P < 0.05 for all etiologies). However, this increase in median age was most eras reflecting a more-advanced population of patients with cirrhosis in the United States with fewer surviving to be listed for LT. We did this in two ways: (1) evaluating the median biochemical MELD score at LT listing by etiology of liver disease and (2) the proportion of candidates wait-listed who either died or dropped off the LT list for worsening clinical status. In general, those with HBV listed for DC had higher laboratory MELD scores at LT WL than individuals with HCV or NASH. The proportion of individuals listed for DC with WL death/dropout or hepatic recovery was unchanged over the eras (P > 0.05 for all).
Discussion
In this population-based study in the United States, we show that since the approval of all oral HCV DAA regimens, there has been an over 30% decrease in the rate of LT WL registration for DC in patients with HCV in the United States. These trends are similar to the trends we previously observed in the HBV population where effective AVT for patients with DC has been available for over a decade. This is in contrast to the growing burden that the NASH population is putting on the health care system, with rates of LT WL Abbreviation: CI, confidence interval. Over the past year, multiple studies have confirmed the safety and impact of achieving SVR with DAA therapy in those with decompensated HCV disease. (10) (11) (12) (13) 20, 21) Investigators from the United Kingdom have recently shown that the ability to reverse hepatic decompensation post-SVR can occur in as little as 6 months, (20) and therefore it is rational to assume that the decrease in HCV WL registration for DC that we have shown is likely a result of the uptake of DAA therapy at the population level. Furthermore, it had been common practice before the availability of DAA therapy for patients being considered for AVT with decompensated HCV disease to be WL for LT because of the concern of further decompensation with IFN-or PI-containing regimens. In the presence of excellent safety of the DAA regimens, there may be more clinicians willing to treat patients with DC without LT WL before starting therapy. We did not find an increase in the proportion of HCV patients removed from the LT WL for hepatic recovery during the DAA era. However, this is likely attributed to the short follow-up time of the cohort post-DAA availability, given that we looked only at those listed in 2014 to allow for 1 year of follow-up. We expect that this trend will become apparent as WL trends are observed into the future. Another potential reason for the secular decrease in LT WL that we observed may be the increasing age of the "baby boomers" who represent the age group with the greatest burden of advanced liver disease, but who will be less eligible for LT WL with aging. This interpretation is supported by the observations of higher median ages at LT WL in the HCV patients over the study period. However, if this were the only explanation for the decrease in WL, then we would have expected that the rate of decline would be similar in both the PI and DAA eras. Given that we observed a more precipitous drop in WL for DC with the approval of DAAs, the decrease from 2014 to 2015 is likely a combination of both the aging HCV population and a higher proportion of HCV patients in receipt of AVT.
We did not observe the same degree of decrease in LT WL registration for the indication of HCC. This is not unexpected given that it has been shown that improvements in underlying hepatic dysfunction secondary to viral suppression occur much more rapidly than does the decrease in risk of HCC. (22, 23) This is likely attributed to the fact that in those achieving viral suppression or cure, duration of disease, underlying cirrhosis, and other nonmodifiable risk factors known to be associated with the development of HCC in the population of patients with cirrhosis, such as age, sex, and the presence of underlying diabetes, persist. (24, 25) Recent data from the Veterans Affairs system suggests that the incidence of HCC after achieving SVR in patients with cirrhosis was 1.4% per year, and this risk was dependent on age and HCV genotype. (26) As more patients with HCV cirrhosis achieving cure after DAA therapy are observed into the future, the risk of HCC will be further quantified, but the impact of DAA therapy on WL for HCC is not yet apparent. Similarly, we hypothesize that in addition to the impact on the LT WL we have observed here, the use of DAA therapy in the HCV population will have other downstream effects in the future. This may include variations in median biochemical MELD score at time of transplant and improvements in posttransplant HCV graft survival attributed to the ability to treat post-LT with DAA regimens. However, this will require several years of observation before these trends will become apparent.
Our results on NASH are consistent with other recent studies indicating that the rates of WL and receipt of LT for NASH is on the rise in the United States. (15, 16) The increase in obesity-and metabolicsyndrome-associated complications, including diabetes, in the U.S. population, are likely responsible for this and NASH given that an LT indication is projected to continue to increase in the years ahead. (27) However, unlike these previous studies, we looked specifically at the difference in the rates based on the listing indication. Importantly, this study shows that in contrast to trends in the populations with HBV and HCV, the indications for listing in the NASH population are increasing for both HCC and DC. As opposed to chronic viral hepatitis, medical therapies that can decrease or reverse the progression of NASH are limited. Therapeutic investigational clinical trials of vitamin E, pioglitazone, metformin, obeticholic acid, and, most recently, cenicriviroc (28) (29) (30) suggest modest improvements in NASH histology with limitedduration therapy. However, there is no current FDAapproved therapy for the NASH indication that can prevent or reverse the development of DC or HCC related to fatty liver during the study period. Additionally, improvements in liver histology have been shown with bariatric surgery in select patient populations, (31, 32) but randomized, clinical trials with prevention or reversal of cirrhosis as the treatment endpoint are lacking. Furthermore, bariatric surgery is controversial in patients with cirrhosis outside of highly specialized centers and therefore not widely available in the United States. Whereas it has been expected for some time that NASH would surpass chronic viral hepatitis B and C as an indication for LT, this analysis shows that, for the indication of DC, this has already occurred in 2015. Furthermore, our study likely underestimates the true burden of complications from NASH in the U.S. population, given that NASH patients have a higher burden of medical comorbidities that may limit their eligibility for LT.
There are several limitations to our study. First, detailed information about medication use is not reported to the OPTN and therefore not included in the SRTR data. Thus, this work is unable to provide a direct link to WL registration and DAA therapy. Furthermore, given that we are looking at secular trends at the population level, other factors associated with a decrease in LT WL could be present that we are unable to account for. However, these would have to be unique to both the underlying liver disease and the indication for LT WL to account for these trends, which, we feel, is unlikely. Second, given that we are examining trends in LT WL and therefore looking solely at individuals who meet criteria for WL, we are unable to comment on individuals with significant comorbid illnesses or with financial or social barriers that limit eligibility for LT. Conversely, however, those eligible for LT WL would likely also have greater access to AVT, so our study is representative of the potential impact of new drug therapies on DC complications, as we have previously observed following the release of safe and effective oral HBV therapies. One final limitation is that the time period studied represents a time during which NASH as a cause for cirrhosis was increasingly recognized. Thus, the increase in WL for NASH could be secondary to the increased recognition of this condition over the past decade, which may have previously been classified as cryptogenic cirrhosis. To try and account for this, we included patients with cryptogenic cirrhosis and a BMI >30; however, though this has also been done by investigators in the past, (33) it remains a limitation. In conclusion, this population-based study shows a significant decrease in LT WL registration for the indication of decompensated HCV disease during the era of DAA therapy in the United States. We expect that, with further implementation and expansion of the Centers for Disease Control and Prevention-recommended screening of the baby-boomer population (born 1945-1965) , linkage to care, and availability and utilization of available DAA regimens, this trend will continue into the future and will likely eliminate HCV as the leading cause for LT in the United States. In contrast, the rising rates of DC and HCC listings for NASH portend a major transplantation need today and in future. Although a large number of investigational therapeutic agents for treatment of NASH are in current clinical development, LT WL for NASH is anticipated to rise in the immediate future until effective, well-tolerated therapy becomes available in this population.
